JP2024516173A5 - - Google Patents
Info
- Publication number
- JP2024516173A5 JP2024516173A5 JP2023564584A JP2023564584A JP2024516173A5 JP 2024516173 A5 JP2024516173 A5 JP 2024516173A5 JP 2023564584 A JP2023564584 A JP 2023564584A JP 2023564584 A JP2023564584 A JP 2023564584A JP 2024516173 A5 JP2024516173 A5 JP 2024516173A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- mlpscs
- composition according
- million
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021901214A AU2021901214A0 (en) | 2021-04-23 | Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells | |
| AU2021901214 | 2021-04-23 | ||
| AU2021902180 | 2021-07-15 | ||
| AU2021902180A AU2021902180A0 (en) | 2021-07-15 | Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells | |
| AU2022900260 | 2022-02-09 | ||
| AU2022900260A AU2022900260A0 (en) | 2022-02-09 | Method for treating acute respiratory distress syndrome (ARDS) in specific patients using mesenchymal lineage precursor or stem cells | |
| AU2022900372 | 2022-02-18 | ||
| AU2022900372A AU2022900372A0 (en) | 2022-02-18 | Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells | |
| PCT/IB2022/053762 WO2022224206A1 (en) | 2021-04-23 | 2022-04-22 | Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516173A JP2024516173A (ja) | 2024-04-12 |
| JP2024516173A5 true JP2024516173A5 (https=) | 2025-05-01 |
Family
ID=81585202
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564582A Pending JP2024516172A (ja) | 2021-04-23 | 2022-04-22 | 間葉系前駆体又は幹細胞を使用する急性呼吸窮迫症候群（ａｒｄｓ）を治療するための方法 |
| JP2023564584A Pending JP2024516173A (ja) | 2021-04-23 | 2022-04-22 | 間葉系前駆体又は幹細胞を使用する特定の患者における急性呼吸窮迫症候群（ａｒｄｓ）を治療するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564582A Pending JP2024516172A (ja) | 2021-04-23 | 2022-04-22 | 間葉系前駆体又は幹細胞を使用する急性呼吸窮迫症候群（ａｒｄｓ）を治療するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20240207323A1 (https=) |
| EP (2) | EP4326294A1 (https=) |
| JP (2) | JP2024516172A (https=) |
| KR (2) | KR20240001172A (https=) |
| AU (2) | AU2022261504A1 (https=) |
| BR (2) | BR112023021840A2 (https=) |
| CA (2) | CA3216129A1 (https=) |
| WO (2) | WO2022224206A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120087868A1 (en) | 2010-10-08 | 2012-04-12 | Gabriele Todd | Nanoparticle-loaded cells |
| SG11202004680UA (en) | 2017-11-22 | 2020-06-29 | Mesoblast Int Sarl | Cellular compositions and methods of treatment i |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US6251295B1 (en) | 1998-01-08 | 2001-06-26 | Nexell Therapeutics Inc. | Method for recirculation washing of blood cells |
| BR112021024310A2 (pt) * | 2019-06-05 | 2022-02-15 | Univ Emory | Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus |
-
2022
- 2022-04-22 BR BR112023021840A patent/BR112023021840A2/pt unknown
- 2022-04-22 AU AU2022261504A patent/AU2022261504A1/en active Pending
- 2022-04-22 JP JP2023564582A patent/JP2024516172A/ja active Pending
- 2022-04-22 US US18/556,845 patent/US20240207323A1/en active Pending
- 2022-04-22 WO PCT/IB2022/053762 patent/WO2022224206A1/en not_active Ceased
- 2022-04-22 CA CA3216129A patent/CA3216129A1/en active Pending
- 2022-04-22 AU AU2022260822A patent/AU2022260822A1/en active Pending
- 2022-04-22 BR BR112023021825A patent/BR112023021825A2/pt unknown
- 2022-04-22 EP EP22721854.2A patent/EP4326294A1/en active Pending
- 2022-04-22 CA CA3216121A patent/CA3216121A1/en active Pending
- 2022-04-22 US US18/556,827 patent/US20240197787A1/en active Pending
- 2022-04-22 EP EP22724876.2A patent/EP4326295A1/en active Pending
- 2022-04-22 JP JP2023564584A patent/JP2024516173A/ja active Pending
- 2022-04-22 KR KR1020237039592A patent/KR20240001172A/ko active Pending
- 2022-04-22 KR KR1020237039593A patent/KR20240001173A/ko active Pending
- 2022-04-22 WO PCT/IB2022/053763 patent/WO2022224207A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Osei et al. | Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD | |
| Mehta et al. | Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities | |
| Hoshino et al. | Redox-active protein thioredoxin prevents proinflammatory cytokine-or bleomycin-induced lung injury | |
| Lacy et al. | Eosinophil cytokines | |
| Mao et al. | Intravenous delivery of bone marrow-derived endothelial progenitor cells improves survival and attenuates lipopolysaccharide-induced lung injury in rats | |
| JP2024516173A5 (https=) | ||
| Strieter et al. | Human alveolar macrophage gene expression of interleukin-8 by tumor necrosis factor-α, lipopolysaccharide, and interleukin-1 β | |
| Standiford et al. | Regulation of human alveolar macrophage-and blood monocyte-derived interleukin-8 by prostaglandin E2 and dexamethasone | |
| Ayala et al. | Role of Interleukin 6 and Transforming Growth Factor–β in the Induction of Depressed Splenocyte Responses Following Sepsis | |
| El-Asrar et al. | Chemokines in the limbal form of vernal keratoconjunctivitis | |
| Khanam et al. | Abnormal innate immunity in acute-on-chronic liver failure: immunotargets for therapeutics | |
| Frankovich et al. | High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes | |
| Su et al. | Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease | |
| Takeshita et al. | Increased levels of circulating soluble CD14 in Kawasaki disease | |
| Oesterreicher et al. | Increased in vitro production and serum levels of the soluble lipopolysaccharide receptor sCD14 in liver disease | |
| Tong et al. | Deep hypothermia therapy attenuates LPS-induced microglia neuroinflammation via the STAT3 pathway | |
| JP2023520233A5 (https=) | ||
| Hu et al. | Interleukin‐18 expression increases in the aorta and plasma of patients with acute aortic dissection | |
| JP2013508408A5 (https=) | ||
| Sarmiento et al. | Ruxolitinib for severe COVID-19-related hyperinflammation in nonresponders to steroids | |
| JP2024516172A5 (https=) | ||
| Klebl et al. | Expression of macrophage‐colony stimulating factor in normal and inflammatory bowel disease intestine | |
| Karimi et al. | Cytokine storm in COVID-19 and the treatment simulacrum | |
| Tabor et al. | Enhanced production of monokines by canine alveolar macrophages in response to endotoxin-induced shock | |
| Wang et al. | Allogeneic stem cell transplantation combined with transfusion of mesenchymal stem cells in primary myelofibrosis: a multicenter retrospective study |